Clinical Trial Update: Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial conducted by GlaxoSmithKline evaluating a second-line intravenous therapy for recurrent platinum-sensitive ovarian, fallopian tube, or peritonea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Snippet

Sponsor: GlaxoSmithKline | Conditions: Peritoneal Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED